Hangzhou Shengyu Biopharmaceutical Technology

Hangzhou Shengyu Biopharmaceutical Technology is a China-based biotechnology company specializing in the discovery and development of innovative small molecule drugs targeting the DNA Damage Response (DDR) pathway. Founded in 2021, the company leverages the concept of synthetic lethality to create precision medicines for oncology, particularly for patients with specific genetic deficiencies like BRCA mutations. Their lead candidate, SY-8505, is a highly selective inhibitor of DNA polymerase theta (POLQ) designed to treat various solid tumors. By utilizing a proprietary DDR-focused drug discovery platform, Shengyu Biopharma aims to overcome drug resistance and provide novel therapeutic options for cancer patients worldwide.